Of the 11 identified DEGs, ACTL6A expression was found to play important roles in ovarian cancer progression and to be closely correlated with adverse prognosis for overall survival (OS) and progression-free survival (PFS) in ovarian cancer patients. The gene discussed is ACTL6A; the disease is ovarian carcinoma.